Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy

FİDAN S., ÇAPKIN E., Arica D., DURAK S., Okatan I. E.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, cilt.24, sa.2, ss.254-259, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/1756-185x.14034
  • Dergi Adı: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.254-259
  • Anahtar Kelimeler: antirheumatic therapy, anti&#8208, tumor necrosis factor therapy, hepatitis B, hepatitis B virus reactivation, hepatitis B virus screening, VIRUS HBV REACTIVATION, OCCULT CARRIERS, PREVENTION, GUIDELINES, SAFETY
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Objective The purpose of this study was to determine hepatitis B virus (HBV) screening rates in patients receiving anti-tumor necrosis factor (TNF)-alpha therapy and the frequency of HBV reactivation in patients with resolved hepatitis B virus infection (hepatitis B surface antigen [HBsAg] negative, hepatitis B core antibody [Anti-HBc] positive).